CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting [Yahoo! Finance]
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting